Johannes Hull - Pliant Therapeutics Chief Officer
| PLRX Stock | USD 13.21 0.09 0.68% |
Insider
Johannes Hull is Chief Officer of Pliant Therapeutics
| Age | 49 |
| Address | 260 Littlefield Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 481 6770 |
| Web | https://pliantrx.com |
Pliant Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2815) % which means that it has lost $0.2815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4752) %, meaning that it created substantial loss on money invested by shareholders. Pliant Therapeutics' management efficiency ratios could be used to measure how well Pliant Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. At this time, Pliant Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 378.4 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 957.1 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Marine Popoff | Hookipa Pharma | N/A | |
| Sunil MD | Sana Biotechnology | 54 | |
| Mr MS | Karyopharm Therapeutics | N/A | |
| Jason Barker | Arcus Biosciences | 49 | |
| Steven Kanner | Caribou Biosciences | 65 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Bernard JD | Sana Biotechnology | 69 | |
| Christopher Garcia | Arcus Biosciences | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| Sharon MBA | Karyopharm Therapeutics | 54 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Nicole Lambert | Arcus Biosciences | 46 | |
| Shanna Peek | Sana Biotechnology | N/A | |
| Carolyn Tang | Arcus Biosciences | 41 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Mark DVM | Fate Therapeutics | 63 | |
| Justin Skoble | Caribou Biosciences | N/A | |
| Robert II | Arcus Biosciences | 51 | |
| Keith MD | X4 Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.28 |
Pliant Therapeutics Leadership Team
Elected by the shareholders, the Pliant Therapeutics' board of directors comprises two types of representatives: Pliant Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pliant. The board's role is to monitor Pliant Therapeutics' management team and ensure that shareholders' interests are well served. Pliant Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pliant Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hal MD, Scientific Board | ||
| Mike Ouimette, Gen Sec | ||
| Rik Derynck, Scientific Board | ||
| Dean MD, Scientific Board | ||
| Johannes Hull, Chief Officer | ||
| MBA MD, CEO Pres | ||
| Christopher Keenan, Vice Communications | ||
| MD MBA, Chief Officer | ||
| Lily Cheung, Chief Officer | ||
| ric MD, Chief Officer | ||
| Mike JD, General Secretary | ||
| Eric MD, Chief Officer | ||
| Craig Muir, Interim Officer | ||
| Bill DeGrado, Scientific Board |
Pliant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pliant Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 460.18 M | ||||
| Shares Outstanding | 60.85 M | ||||
| Shares Owned By Insiders | 2.91 % | ||||
| Shares Owned By Institutions | 97.09 % | ||||
| Number Of Shares Shorted | 7.24 M | ||||
| Price To Book | 2.33 X | ||||
| Price To Sales | 3,050 X | ||||
| Revenue | 1.58 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.